Skip to main content
SpringerLink
Log in

Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma

  • Living reference work entry
  • First Online:
Cutaneous Melanoma

Abstract

Recent advances in molecular targeted therapy and immunotherapy have revolutionized the treatment of metastatic melanoma. Combined BRAF inhibitors and MEK inhibitors have been approved for the treatment of BRAF-mutant metastatic melanoma and have become a new standard of care. However, acquired resistance is still a significant concern with BRAF and MEK inhibitor combination therapy. Checkpoint inhibitors appear to produce durable responses in patients with both BRAF-mutant and wild-type melanoma, with the combination of anti-PD-1 and anti-CTLA-4 appearing to be particularly beneficial relative to single-agent anti-PD-1 in patients with BRAF-mutant tumors. The increasing number of effective treatment options for patients with BRAF-mutant metastatic melanoma has led to new questions regarding which agent/approach or sequence of agents is optimal and in which patient and whether combinations of approaches (MAPK inhibition plus checkpoint inhibition) could produce superior outcomes relative to the use of agents in sequence. MAPK inhibitors can provide early and high rates of response, but with a shorter duration of effect. In contrast, immune checkpoint inhibitors have slower onset of action but offer more durable responses and potentially longer-term disease control. Retrospective data appear to suggest that immunotherapy should be the first option in the majority of patients with BRAF-mutant melanoma, although such conclusions are subject to considerable biases and are therefore far from certain. Several randomized trials are prospectively evaluating the sequence questions and will soon provide more definitive data for the population as a whole and hopefully for specific subsets of patients and particular sequencing schedules. The triple combinations of BRAF/MEK inhibitors with PD-1 pathway blockers appear promising, with several combinations being evaluated in clinical trials. Preliminary results have demonstrated high response rates and good tolerability, although the ability of such regimens to produce the sustained off-treatment responses characteristic of immunotherapy remains unknown. There remains an urgent need to complete ongoing clinical trials so that we can provide a rational treatment approach for each patient in the foreseeable future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Ackerman A, Klein O, McDermott DF et al (2014) Outcomes of patients with metastatic melanoma treated with immuno-therapy prior to or after BRAF inhibitors. Cancer 120:1695–1701

    Article  CAS  PubMed  Google Scholar 

  • Algazi A, Othus M, Daud A et al (2015) SWOG S1320: a randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAF V600E/k mutant melanoma. J Clin Oncol 33(Suppl):TPS9093

    Google Scholar 

  • Ascierto PA, Simeone E, Giannarelli D et al (2012) Sequencing of BRAF inhibitors and ipilimumab in patients with meta-static melanoma: a possible algorithm for clinical use. J Transl Med 10:107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ascierto PA, Simeone E, Grimaldi AM et al (2013) Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med 11:61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ascierto PA, Simeone E, Sileni VC et al (2014a) Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Investig 32:144–149

    Article  CAS  Google Scholar 

  • Ascierto PA, Simeone E, Sileni VC et al (2014b) Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 12:116

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ascierto PA, McArthur GA, Dréno B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260

    Article  CAS  PubMed  Google Scholar 

  • Ascierto PA, Del Vecchio M, Robert C et al (2017) Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 18:611–622

    Article  CAS  PubMed  Google Scholar 

  • Ascierto PA, Ferrucci PF, Stephens R et al (2018) KEYNOTE-022 Part 3: Phase 2 randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. Ann Oncol 29 (suppl_8): viii442–viii466. https://doi.org/10.1093/annonc/mdy289

  • Atkins MB, Lotze MT, Dutcher JP, et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol; 17:2105–16

    Article  CAS  PubMed  Google Scholar 

  • Atkins M, McDermott D, Tarhini A et al (2018) Matching-adjusted indirect comparison of nivolumab + ipilimumab and BRAF+MEK inhibitors for the treatment of BRAF-mutant treatment-naive advanced melanoma. In: Proceedings AACR annual meeting 2018, Chicago, 78(Suppl), 14–18 April 2018. https://doi.org/10.1158/1538-7445.AM2018-3639

    Article  Google Scholar 

  • Atkinson V et al (2015) Two-Year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (mel) receiving nivolumab (nivo) or dacarbazine (DTIC) in CheckMate-066. Presented at the Society for Melanoma Research 2015 International Congress, San Francisco, 18–21 November 2015

    Google Scholar 

  • Boni A, Cogdill AP, Dang P et al (2010) Selective BRAF V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213–5219

    Article  CAS  PubMed  Google Scholar 

  • Callahan MK, Kluger H, Postow MA et al (2018) Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol 36:391–398

    Article  CAS  PubMed  Google Scholar 

  • Carlino MS, Vanella V, Girgis C et al (2016) Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer 115:1280–1284

    Article  PubMed  PubMed Central  Google Scholar 

  • Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37–40

    Article  CAS  PubMed  Google Scholar 

  • Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Christiansen SA, Swoboda D, Gardner K et al (2018) Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy. J Clin Oncol 36(Suppl):abstr 9554

    Article  Google Scholar 

  • Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147

    Article  CAS  PubMed  Google Scholar 

  • Daud A, Weber J, Sosman J et al (2015a) Updated overall survival (OS) results for BRF113220, a phase I–II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). J Clin Oncol 33(Suppl):Abstract 9036

    Google Scholar 

  • Daud A, Ribas A, Robert C et al (2015b) Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 33(Suppl):Abstract 9005

    Google Scholar 

  • Daud A, Pavlick AC, Ribas A et al (2017) Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib (C) combined with vemurafenib (V) in BRAF V600-mutated melanoma. Pigment Cell Mel Res 31. https://doi.org/10.1111/pcmr.12656

  • Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  CAS  PubMed  Google Scholar 

  • Davies MA, Saiag P, Robert C et al (2017) Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18:863–873

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dummer R, Ascierto PA, Gogas HJ et al (2018a) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:603. https://doi.org/10.1016/S1470-2045(18)30142-6

    Article  CAS  PubMed  Google Scholar 

  • Dummer R, Schadendorf D, Nathan P et al (2018b) The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: first efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i. http://www.abstractsonline.com/pp8/#!/4562/presentation/11158

  • Eggermont AMM, Blank CU, Mandala M et al (2018) Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 378:1789–1801

    Article  CAS  PubMed  Google Scholar 

  • Farooq A, Zhou MM (2004) Structure and regulation of MAPK phosphatases. Cell Signal 16:769–779

    Article  CAS  PubMed  Google Scholar 

  • Ferrari de Andrade L, Ngiow SF, Stannard K et al (2014) Natural killer cells are essential for the ability of BRAF inhibitors to control BRAF V600E-mutant metastatic melanoma. Cancer Res 74:7298–7308

    Article  CAS  PubMed  Google Scholar 

  • Flaherty K, Infante J, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694–1703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Frederick DT, Piris A, Cogdill AP et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19:1225–1231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goel VK, Lazar AJ, Warneke CL et al (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126:154–160

    Article  CAS  PubMed  Google Scholar 

  • Gonzalez M, Menzies AM, Saw R et al (2018) Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: a phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial). J Clin Oncol 36(Suppl):abstr TPS9604

    Article  Google Scholar 

  • Hamid O, Patel M, Hodi S et al (2015) Preliminary clinical safety, tolerability and activity of atezolizumab (anti-PDL1) combined with vemurafenib in BRAF V600 metastatic melanoma Pigment. Cell Melanoma Res. https://doi.org/10.1111/pcmr.12419

  • Hamid O, Puzanov I, Dummer R et al (2017) Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer 86:37–45

    Article  CAS  PubMed  Google Scholar 

  • Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomized controlled trial. Lancet 380:358–365

    Article  CAS  PubMed  Google Scholar 

  • Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi FS, Chesney J, Pavlick AC et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558–1568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hu-Lieskovan S, Mok S, Homet Moreno B et al (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 7:279ra41

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Infante J, Kim TM, Friedmann J et al (2016) Safety and clinical activity of atezolizumab combined with cobimetinib in metastatic melanoma. Presented at the Society for Melanoma Research 2016 Congress, Boston, 6–9 November 2016

    Google Scholar 

  • Johnson DB, Menzies AM, Zimmer L et al (2015) Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 51:2792–2799

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnson DB, Pectasides E, Feld E et al (2017) Sequencing treatment in BRAF V600 mutant melanoma: anti-PD-1 before and after BRAF inhibition. J Immunother 40: 31–35

    Article  CAS  PubMed  Google Scholar 

  • Joseph RW, Sullivan RJ, Harrell R et al (2012) Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35:66–72

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Katz M, Amit I, Yaden Y et al (2007) Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 1773:1161–1176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Korn EL, Liu PY, Lee SJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527–534

    Article  PubMed  Google Scholar 

  • Larkin J, Ascierto P, Dreno B et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1866

    Article  PubMed  CAS  Google Scholar 

  • Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Larkin JMG, McArthur GA, Ribas A et al (2016) Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM). J Clin Oncol 34(15 Suppl):9528–9528

    Article  Google Scholar 

  • Larkin JMG, Lewis KD, Ribas A et al (2017) Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAF V600-mutated metastatic melanoma (mM). J Clin Oncol 35(15 Suppl): 9556–9556

    Article  Google Scholar 

  • Long G, Stroyakoversuskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371: 1877–1888

    Article  PubMed  CAS  Google Scholar 

  • Long G, Stroyakoversuskiy D, Gogas H et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomized controlled trial. Lancet 386:444–451

    Article  CAS  PubMed  Google Scholar 

  • Long GV, Flaherty KT, Stroyakoversuskiy D et al (2017a) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28:1631–1639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Long GV, Atkinson V, Cebon J et al (2017b) Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol 18:1202–1210

    Article  CAS  PubMed  Google Scholar 

  • Long GV, Hauschild A, Santinami M et al (2017c) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377: 1813–1823

    Article  CAS  PubMed  Google Scholar 

  • Long GV, Schachter J, Ribas A et al (2018a) 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. J Clin Oncol 36(Suppl):abstr 9503

    Article  Google Scholar 

  • Long GV, Atkinson V, Lo S et al (2018b) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19:672–681

    Article  CAS  PubMed  Google Scholar 

  • Lu W, Burton L, Larkin J et al (2018) Elevated levels of BRAF V600 Mutant circulating tumor DNA and circulating hepatocyte growth factor are associated with poor prognosis in patients with metastatic melanoma. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00168

  • Maio M, Grob JJ, Aamdal S et al (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33:1191–1196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mateus C, Routier E, Roy S et al (2014) Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613. J Clin Oncol 32(Suppl):TPS9114

    Google Scholar 

  • Minor DR, Puzanov I, Callahan MK et al (2015) Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res 28:611–612

    Article  PubMed  PubMed Central  Google Scholar 

  • Moriceau G, Hugo W, Hong A et al (2015) Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27:240–256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Olson D, Luke JJ, Hallmeyer S et al (2018) Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel). J Clin Oncol 36(Suppl):abstr 9514

    Article  Google Scholar 

  • Ott PA, Henry T, Baranda SJ et al (2013) Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother 62:811–822

    Article  CAS  PubMed  Google Scholar 

  • Pavlick A, Ribas A, Gonzalez R et al (2015) Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. J Clin Oncol 33(Suppl):Abstract 9020

    Google Scholar 

  • Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017

    Article  PubMed  PubMed Central  Google Scholar 

  • Puzanov I, Milhem MM, Andtbacka RHI et al (2015a) Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIBIV melanoma. J Clin Oncol 33(Suppl):abstr 9063

    Google Scholar 

  • Puzanov I, Ribas A, Daud A et al (2015b) Pembrolizumab for advanced melanoma: effect of BRAF V600 mutation status and prior BRAF inhibitor therapy. Pigment Cell Melanoma Res J (abstract) 392–393

    Google Scholar 

  • Ribas A, Hodi FS, Callahan M et al (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:1365–1366

    Article  CAS  PubMed  Google Scholar 

  • Ribas A, Gonzalez R, Pavlick A et al (2014) Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 15:954–965

    Article  CAS  PubMed  Google Scholar 

  • Ribas A, Puzanov I, Dummer R et al (2015a) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ribas A, Butler M, Lutzky J et al (2015b) Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol 33(Suppl):Abstract 3003

    Google Scholar 

  • Ribas A, Hodi FS, Lawrence D et al (2017) KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma. Ann Oncol 28(Suppl 5):Abstract 2160

    Google Scholar 

  • Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526

    Article  CAS  PubMed  Google Scholar 

  • Robert C, Schachter J, Long GV et al (2015a) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532

    Article  CAS  PubMed  Google Scholar 

  • Robert C, Long GV, Brady B et al (2015b) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330

    Article  CAS  PubMed  Google Scholar 

  • Robert C, Karaszewska B, Schachter J et al (2015c) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39

    Article  PubMed  CAS  Google Scholar 

  • Robert C, Karaszewska B, Schachter J et al (2015d) Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib and trametinib versus vemurafenib as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Presented at European Cancer Congress, Vienna, 25–29 September 2015, abstr 3301. http://www.ecco-org.eu/Vienna2015/Scientific-Programme/Searchable-Programme?trackid=00181#anchorScpr

  • Robert C, Grob J-J, Schadendorf D et al (2017) Outcomes and characteristics of patients who achieved a complete response with dabrafenib and trametinib. Pigment Cell Mel Res 31. https://doi.org/10.1111/pcmr.12656

  • Robert C, Ribas A, Hamid O et al (2018) Durable complete response after discontinuation of Pembrolizumab in patients with metastatic melanoma. J Clin Oncol 36:1668–1674

    Article  PubMed  Google Scholar 

  • Saab K, Mooradian M, Wang DY et al (2018) Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy. J Clin Oncol 36(Suppl):abstr 9540

    Article  Google Scholar 

  • Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889–1894

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schadendorf D, Wolchok JD, Hodi FS et al (2017) Efficacy and safety outcomes in patients with advanced Melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807–3814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schilling B, Paschen A (2013) Immunological consequences of selective BRAF inhibitors in malignant melanoma: neutralization of myeloid-derived suppressor cells. Oncoimmunology 2(8):e25218

    Article  PubMed  PubMed Central  Google Scholar 

  • Schreuer MS, Chevolet IL, Jansen YJ et al (2015) Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Res 25:68–74

    Article  CAS  PubMed  Google Scholar 

  • Selby MJ, Engelhardt JJ, Johnston RJ et al (2016) Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One 11:e0161779

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Simeone E, Grimaldi AM, Festino L et al (2017) Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. Oncoimmunology; 6:e1283462

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Solit DB, Garraway LA, Pratilas CA et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362

    Article  CAS  PubMed  Google Scholar 

  • Sullivan R, Weber J, Patel S et al (2015) A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol 33(Suppl):abstr 9007

    Google Scholar 

  • Sullivan RJ, Gonzalez R, Lewis KD et al (2017) Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAF V600-mutant metastatic melanoma (mel): updated safety and clinical activity. J Clin Oncol 35(15 Suppl):abstr 3063

    Article  Google Scholar 

  • Sznol M, Kluger HM, Callahan MK et al (2014) Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 32(Suppl):9003 abstr

    Article  Google Scholar 

  • Tan AC, Emmett L, Lo S et al (2018) Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM). J Clin Oncol 36(Suppl):abstr 9517

    Article  Google Scholar 

  • Tarhini AA, McDermott DF, Ambavane A et al (2018) Clinical and economic outcomes associated with sequential treatment in BRAF-mutant advanced melanoma patients. J Clin Oncol 36(Suppl):abstr 9538

    Article  Google Scholar 

  • Tawbi HA-H, Amaria RN, Glitza IC et al (2018) Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM). J Clin Oncol 36(Suppl):abstr 9560

    Article  Google Scholar 

  • Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207–212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsai J, Lee JT, Wang W et al (2008) Discovery of a selective inhibitor of oncogenic BRaf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105: 3041–3046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ugurel S, Loquai C, Kähler K et al (2015) A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Ann Oncol 26:573–582

    Article  CAS  PubMed  Google Scholar 

  • Ugurel S, Röhmel J, Ascierto PA et al (2017) Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer 83:247–257

    Article  PubMed  Google Scholar 

  • Vanderwalde AM, Latkovic-Taber M, Hu-Lieskovan S et al (2018) Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616). J Clin Oncol 36(Suppl):abstr TPS9597

    Article  Google Scholar 

  • Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384

    Article  CAS  PubMed  Google Scholar 

  • Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824–1835

    Article  CAS  PubMed  Google Scholar 

  • Wilmott JS, Long GV, Howle JR et al (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386–1394

    Article  CAS  PubMed  Google Scholar 

  • Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wongchenko MJ, Ribas A, Ascierto PAA et al (2018) Effects of molecular heterogeneity on survival of patients with BRAF V600-mutated melanoma treated with vemurafenib with or without cobimetinib in the coBRIM study. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00242

  • Xia CY, Wang DY, Mason R et al (2018) Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma. J Clin Oncol 36(Suppl):abstr 9532

    Article  Google Scholar 

  • Yan Y, Robert C, Larkin J et al (2016) Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAF V600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. Ann Oncol 27:379–400

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy

    Paolo A. Ascierto

  2. Department of Medical Oncology, Georgetown University Medical Center, Washington, DC, USA

    Michael B. Atkins

Authors
  1. Paolo A. Ascierto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael B. Atkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo A. Ascierto .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, University of Texas Southwestern, Dallas, TX, USA

    Charles Balch

  2. Division of Surgery, UT MD Anderson Cancer Center, Houston, TX, USA

    Jeffrey Gershenwald

  3. Melanoma Institute of Australia, Wollstonecraft, Australia

    John Thompson

  4. Georgetown Medical Center, Washington, DC, USA

    Michael Atkins

  5. Melanoma and Skin Cancer Program, University of Pittsburgh, Pittsburgh, PA, USA

    John Kirkwood

  6. University of Sydney, Sydney, NSW, Australia

    Richard Kefford

  7. Department of Dermatology, Harvard Medical Center, Boston, MA, USA

    Arthur Sober

  8. Department of Dermatology, Memorial Sloan Kettering, New York, NY, USA

    Allan Halpern

  9. Department of Dermatology, University Hospital, Tübingen, Tübingen, Germany

    Claus Garbe

  10. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown NSW, Australia

    Richard Scolyer

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ascierto, P.A., Atkins, M.B. (2019). Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. In: Balch, C., et al. Cutaneous Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-319-46029-1_61-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46029-1_61-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-46029-1

  • Online ISBN: 978-3-319-46029-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation